Hair papilla cell activator and hair agent

The use of miR-27a-3p, miR-140-5p, and miR-224-5p in a dermal papilla cell activator effectively addresses the inadequacies of existing hair growth and gray hair prevention solutions by activating dermal papilla cells, thereby promoting hair growth and preventing gray hair through targeted gene expression.

WO2024242203A1PCT designated stage expired Publication Date: 2024-11-28ASFREYA INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019306
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current hair growth and gray hair prevention solutions are inadequate, as they fail to effectively activate dermal papilla cells, which are crucial for hair growth and maintenance, and often rely on non-specific active ingredients.

Method used

A dermal papilla cell activator containing specific microRNAs (miR-27a-3p, miR-140-5p, and miR-224-5p) is developed to significantly increase the expression of genes related to hair growth and gray hair prevention, such as COL17A1 and VEGF, by administering these miRNAs transdermally or subcutaneously.

Benefits of technology

The activation of dermal papilla cells leads to enhanced hair growth and prevention of gray hair by increasing the expression of key genes, promoting hair health and maintenance through targeted miRNA administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024019306_28112024_PF_FP_ABST
    Figure JP2024019306_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The objective of the present invention is to provide a novel component that activates hair papilla cells and can be used, for example, for hair growth, hair nourishment, and prevention of gray hair. The hair papilla cell activator of the present invention is characterized by containing at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p.
Need to check novelty before this filing date? Find Prior Art

Description

Hair papilla cell activator and hair agent

[0001] The present invention relates to a hair papilla cell activator and a hair preparation.

[0002] Thinning hair, gray hair, and the like are hair problems that occur regardless of gender or age, and are generally thought to be caused by, for example, stress, aging, diet, sleep, genetics, etc. In recent years, various active ingredients have been searched for to address these problems, and compositions containing low molecular weight compounds have been reported (Patent Document 1).

[0003] JP 2023-050280 A

[0004] Therefore, an object of the present invention is to provide a new component that activates hair papilla cells and can be used for, for example, hair growth, hair care, and prevention of gray hair.

[0005] To achieve the above object, the dermal papilla cell activator of the present invention is characterized by containing at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p.

[0006] The hair agent of the present invention is characterized by containing the dermal papilla cell activator of the present invention.

[0007] The present inventors discovered that specific miRNAs can activate dermal papilla cells, leading to the establishment of the present invention. According to the present invention, dermal papilla cells can be activated, which makes it possible to promote hair growth, prevent gray hair, and the like.

[0008] FIG. 1 is a graph showing the expression levels of the VEGF gene and the COL17A1 gene in hair papilla cells in the presence of miRNA in Example 1.

[0009] [1] A hair dermal papilla cell activator comprising at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. [2] A hair agent comprising the hair dermal papilla cell activator according to [1]. [3] The hair agent according to [2], which is for hair growth and hair regrowth. [4] The hair agent according to [2] or [3], which is for preventing gray hair. [5] A method for activating hair dermal papilla cells, comprising the step of administering to the scalp at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. [6] The method for activating hair dermal papilla cells according to claim 5, wherein the administration to the scalp is transdermal or subcutaneous. [7] At least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in activating hair papilla cells. [8] At least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in manufacturing a hair papilla activator.

[0010] Unless otherwise specified, terms used in this specification can be used in the sense commonly used in the art.

[0011] As used herein, "hair improvement" refers to hair-related phenomena such as hair growth, hair care, hair restoration, hair loss, and graying, which are the subject of improvement. Hair growth means, for example, growing hair, hair restoration means, for example, growing hair, and hair restoration means, for example, suppressing hair loss and protecting hair. "Improvement" means, for example, maintaining the current state, improving (improving the condition, promoting), and preventing deterioration (preventing a worsening condition), etc. Prevention of deterioration includes, for example, suppressing deterioration and delaying deterioration. In the present invention, hair improvement also includes the meaning of improving the scalp. In the present invention, improvement also includes the meaning of treatment. Treatment may mean, for example, suppression of deterioration, alleviation (improvement), remission, or cure (complete recovery) of the target symptom, and may also include "prevention" in a broad sense. "Prevention" includes, for example, suppressing the onset of the target symptom, delaying the onset, etc. In the present specification, for example, when "treatment" is defined in the narrow sense, "treatment" in the present specification can be read as, for example, prevention.

[0012] The present invention will be described below with reference to specific examples, but is not limited to these examples. The examples in each invention can be used interchangeably.

[0013] (1) Dermal papilla cell activator As described above, the dermal papilla cell activator of the present invention is characterized by comprising at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. In the present invention, miR-27a-3p, miR-140-5p, and miR-224-5p are hereinafter referred to as the miRNA of the present invention.

[0014] In the present invention, activation of dermal papilla cells means, for example, significantly increasing the expression of at least one of the COL17A1 gene and the VEGF gene in dermal papilla cells compared to dermal papilla cells in the absence of the miRNA of the present invention. The COL17A1 gene and the VEGF gene are known to be genes involved in hair growth, hair regrowth, and prevention of gray hair, respectively.

[0015] COL17A1 (Gene Symbol) has the gene name collagen type XVII alpha 1. VEGF has the gene symbol VEGFA and the gene name vascular endothelial growth factor A.

[0016] miR-27a-3p, miR-140-5p, and miR-224-5p are microRNAs (miRNAs). These three miRNAs are registered in the database (MiRBase: https: / / www.mirbase.org) under the following accession numbers: miR-27a-3p Accession No. MIMAT0000084 miR-140-5p Accession No. MIMAT0000431 miR-224-5p Accession No. MIMAT0000281

[0017] Since the sequence of the miRNA is known, it can be synthesized by, for example, organic chemical techniques or genetic engineering techniques. The miRNA may be, for example, chemically modified or unmodified.

[0018] In the hair papilla cell activator of the present invention, the miRNA of the present invention is preferably, for example, miRNA that is not encapsulated in biological vesicles, and can also be called free miRNA. The hair papilla cell activator of the present invention can be, for example, in a form that contains the miRNA of the present invention and does not contain biological vesicles.

[0019] The hair follicle dermal papilla cell activator of the present invention comprises, as an active ingredient, at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. The hair follicle dermal papilla cell activator of the present invention may contain, for example, only the active ingredient, or may contain the active ingredient and other additive ingredients.

[0020] The hair follicle dermal papilla cell activator of the present invention may contain, for example, any one of the three types of miRNA, or a combination of any two of them (a combination of miR-27a-3p and miR-140-5p, a combination of miR-27a-3p and miR-224-5p, or a combination of miR-140-5p and miR-224-5p), or may contain all three types of miRNA. When two types of miRNA or three types of miR are used in combination, the ratio between them is not particularly limited.

[0021] The dermal papilla cell activator of the present invention may contain only the miR of the present invention as an active ingredient, or may contain the miRNA of the present invention and another dermal papilla cell activating component. The other dermal papilla cell activating component may be any component that activates dermal papilla cells, and may be, for example, an already known component or a component that will become publicly known after the filing of the present application.

[0022] The dermal papilla cell activator of the present invention can be used, for example, to improve the hair of a living subject, and as a specific example, can be used as the hair agent of the present invention.

[0023] The hair papilla cell activator of the present invention is used, for example, by administering it to a living subject, such as a human or a non-human animal, and examples of the non-human animal include mammals such as mice, rats, dogs, cats, monkeys, rabbits, cows, goats, and camels.

[0024] The administration to a living body is, for example, parenteral. Examples of parenteral administration include transdermal administration and subcutaneous administration. Examples of transdermal administration include application to the scalp, and examples of subcutaneous administration include injection into the scalp (e.g., subcutaneous tissue).

[0025] The dosage of the hair papilla activator of the present invention is not particularly limited, and is preferably administered in a pharmaceutically effective amount. The pharmaceutically effective amount can be determined, for example, depending on the route of administration, the type of hair-related improvement item, the presence or absence, severity, age, sex, etc. Furthermore, the content of the miRNA of the present invention in the hair papilla cell activator of the present invention is not particularly limited, and is preferably administered in a pharmaceutically effective amount, for example.

[0026] As a specific example, when the hair papilla cell activator of the present invention is intended for application to the scalp, the miRNA of the present invention can be applied to the entire scalp at a concentration of 0.1 to 100 nmol / L, and the number of applications per day can be, for example, once. Furthermore, the amount of miRNA of the present invention applied per day can be, for example, 0.1 to 100 nmol / L over the entire scalp, and the number of applications per day can be, for example, once. Taking the hair growth cycle into consideration, the application interval can be, for example, once per week, once per month, or once every three months. As described above, the content of the miRNA of the present invention in the hair papilla cell activator of the present invention is not particularly limited, and can be formulated to satisfy, for example, the dosages exemplified above. Furthermore, the concentration of the miRNA of the present invention in the hair papilla cell activator of the present invention is not particularly limited, and can be, for example, a concentration that allows for use as is, or a concentration that allows for dilution at the time of use.

[0027] The hair papilla cell activator of the present invention may contain, for example, the active ingredient and other additive components, as described above. Examples of the additive components include pharmaceutically acceptable ingredients. Specific examples include excipients and carriers (base materials). Examples of the excipients and carriers include aqueous solvents such as water, physiological saline, and buffer solutions; oils and fats such as soybean oil; petrolatum; alcohols such as glycerol; sugars such as maltose, dextrose, and dextrin; sugar alcohols such as xylitol; phospholipids; and liposomes. Other examples of the additive components include binders, disintegrants, surfactants, emulsifiers, antioxidants, lubricants, humectants, thickeners, stabilizers, UV filters, antiseptics, preservatives, vitamins, minerals, and colorants. The additive components may also include, for example, DDSs such as liposome preparations, a specific example of which is phospholipid nanoparticles.

[0028] The dosage form of the dermal papilla cell activator of the present invention is not particularly limited and can be appropriately selected depending on the administration route. Specific examples of the dosage form include topical preparations (external medications) and injections. The topical preparations include transdermal preparations, and transdermal preparations are preferred as a form to be applied to the scalp. Examples of the form of the topical preparation include solutions, emulsions, gels, sols, ointments, and the like.

[0029] The hair papilla cell activator of the present invention may be, for example, a pharmaceutical composition. The pharmaceutical composition may be, for example, a drug, a quasi-drug, or a health product.

[0030] (2) Hair Agent As described above, the hair agent of the present invention is characterized by containing the dermal papilla cell activator of the present invention, and specifically, by containing the miRNA of the present invention, i.e., at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. The same description as for the dermal papilla cell activator of the present invention can be applied to the hair agent of the present invention.

[0031] By containing the miRNA of the present invention, the hair agent of the present invention can increase the expression of genes related to hair growth, hair care, prevention of gray hair, and the like, as described above. Therefore, the hair agent of the present invention can be used, for example, to improve hair conditions. Since the hair agent of the present invention can improve, for example, hair-related symptoms, it can also be called a hair improvement agent or a hair condition improvement agent.

[0032] (3) Method for Activating Dermal Papilla Cells and Hair Improvement Method The method for activating dermal papilla cells of the present invention is characterized by contacting dermal papilla cells with the miRNA of the present invention, i.e., at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p. In this embodiment, the miRNA of the present invention can be read as, for example, the dermal papilla activator of the present invention.

[0033] The method for activating hair papilla cells of the present invention may be used, for example, in vitro or in vivo.

[0034] The method for activating dermal papilla cells of the present invention includes, for example, in vitro, a step of allowing dermal papilla cells to coexist with the miRNA of the present invention. The step preferably involves, for example, allowing the dermal papilla cells to coexist with the miRNA of the present invention in a medium and culturing them. The type of medium and culture conditions are not particularly limited, and for example, general conditions for dermal papilla cells can be used.

[0035] Furthermore, in the case of in vivo, the method for activating hair papilla cells of the present invention includes an administration step of administering the miRNA of the present invention to a living body. The administration step may be, for example, oral administration or parenteral administration, and is preferably parenteral administration. Examples of the parenteral administration include transdermal administration and subcutaneous administration. Transdermal administration includes, for example, application to the scalp, and subcutaneous administration includes, for example, injection under the scalp (e.g., subcutaneous tissue). For the parenteral administration, application to the scalp is preferred. The conditions for administering the miRNA of the present invention are not particularly limited, and the conditions exemplified for the hair papilla cell activator of the present invention can be used.

[0036] According to the present invention, dermal papilla cells in a living body can be activated by administering the miRNA of the present invention to the living body. Specifically, for example, the expression of at least one of the COL17A1 gene and the VEGF gene in dermal papilla cells in the living body can be significantly increased, thereby activating the dermal papilla cells.

[0037] The hair improvement method of the present invention is characterized by comprising an administration step of administering the miRNA of the present invention to a living body. The miRNA of the present invention can be interpreted as, for example, the hair papilla activator of the present invention or the hair agent of the present invention.

[0038] The conditions for administering the miRNA of the present invention are not particularly limited, and the conditions exemplified for the dermal papilla cell activator of the present invention can be used. The hair improvement method of the present invention can also be referred to as a hair care method, for example, and hair care also includes scalp care.

[0039] According to the present invention, hair can be improved by administering the miRNA of the present invention to a living body. As described above, hair improvement includes, for example, hair growth, hair care, and improvement of gray hair, and specific examples include maintenance or improvement of hair growth, maintenance or improvement of hair care, prevention of gray hair, and inhibition of the progression of gray hair.

[0040] (4) Uses The present invention relates to use of at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in activating dermal papilla cells. The present invention also relates to use of at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for producing a dermal papilla cell activator.

[0041] The present invention relates to the use of at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in hair improvement. The present invention also relates to the use of at least one miR selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for producing a hair agent.

[0042] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these.

[0043] Example 1 The miRNAs of the present invention, miR-27a-3p, miR-140-5p, and miR-224-5p, were confirmed to increase the expression of the COL17A1 gene and the VEGF gene.

[0044] (Reagents and conditions) Human follicle dermal papilla cells (HFDPC): Product name 602-05A, Sigma Culture medium: Hair follicle dermal papilla cell growth medium, Product name 611-500, dedicated culture medium, Sigma Collagen-coated flask: Product name Collagen Coated T-75 Flask (125-75), Corning Culture conditions: 37°C, 5% CO 2 , 95% Air

[0045] First, HFDPCs were pre-cultured in 6 mL of the medium in a T-25 flask for 72 hours, and 6 mL of the pre-cultured culture solution was added to the flask containing 6 mL of fresh medium. After 18 hours of culture, the miRNA was added so that the final concentration in the medium was 10 nmol / L. When adding the miRNA, an introduction reagent (trade name JetPEI (registered trademark), manufactured by PPU) was added according to the manufacturer's instructions to introduce the miRNA into the cells. After adding the miRNA, the cells were further cultured for 72 hours, and HFDPCs were recovered (N=2).

[0046] RNA was then extracted from the recovered HEDPCs, and the expression levels of the COL17A1 gene (Assay ID: Hs00990076_g1) and VEGF gene (Assay ID: Hs00900054_m1) were confirmed using TaqMan® Gene Expression Assays. The expression levels of each gene were also confirmed in the same manner for HEDPCs cultured in the absence of miR as a control (N=2). The expression level of each gene in the control was set to 1, and the relative expression level of each gene in cells cultured in the presence of each miR was calculated. These results are shown in the graph in Figure 1.

[0047] FIG. 1 is a graph showing the relative expression levels of the COL17A1 gene and the VEGF gene, with the top graph showing the relative expression level of the COL17A1 gene and the bottom graph showing the relative expression level of the VEGF gene. In each graph, the vertical axis represents the relative expression level. As shown in FIG. 1, increased expression was confirmed for all genes by culturing HEDPCs in the presence of each miR. Among these, miR-140-5p and miR-224-5p showed relatively high expression levels, with miR-224-5p in particular showing a significant increase in expression level. These genes are known to be involved in hair growth, hair care, and the prevention of graying. Therefore, it can be said that the miRs of the present invention can promote hair growth, hair care, and the prevention of graying by promoting the expression of these genes.

[0048] Although the present invention has been described above with reference to the embodiments, the present invention is not limited to the above-described embodiments. Various modifications that can be understood by those skilled in the art can be made to the configuration and details of the present invention within the scope of the present invention.

[0049] This application claims priority based on Japanese Patent Application No. 2023-85976, filed May 25, 2023, the disclosure of which is incorporated herein by reference in its entirety.

[0050] According to the present invention, hair papilla cells are activated, and for example, hair growth, hair care, and prevention of gray hair are possible.

Claims

1. A hair papilla cell activator comprising at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p.

2. A hair tonic comprising the hair papilla cell activator according to claim 1.

3. The hair preparation according to claim 2, which is for hair growth and hair regrowth.

4. The hair preparation according to claim 2 or 3, which is for preventing gray hair.

5. A method for activating hair follicle papilla cells, comprising the step of administering to the scalp at least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p.

6. The method for activating hair papilla cells according to claim 5, wherein administration to the scalp is percutaneous administration or subcutaneous administration.

7. At least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in activating hair follicle papilla cells.

8. At least one miRNA selected from the group consisting of miR-27a-3p, miR-140-5p, and miR-224-5p for use in the manufacture of a hair papilla activator.

Citation Information

Patent Citations

  • Composition for hair growth and hair growth promoting method

    JP2023050280A

  • Method for calculation of heat transmission between metal mold and green tire

    JP2023085976A

  • Exosome hair growth preparation loaded with miRNAs and application of exosome hair growth preparation

    CN117904193A

  • Compositions and methods relating to exosomes derived from human dermal papilla cells

    WO2021202459A1